VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Sold it all

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Nov 01, 2022 10:05am

82 Views

Post# 35062709

RE:RE:RE:RE:RE:RE:Sold it all

G1945V wrote:

GrahamB wrote:

theNorm wrote:
Wars over buddy, you lost. Being recommend by NICE means VPT is now the standard of care for cardiac patients in the UK replacing expensive MRI imaging. It's all explained at ceo ca

As I said to Norm at the time. His statemnet was not based in fact.
I indicated I believed VPT would not recieve a positive review based on limited studies.

The result is:

"Key uncertainties around the evidence or technology are that only 1 study was done in the UK and is generalisable to the NHS, and there is limited evidence assessing left ventricular and atrial volumes. One study also found that agreement between VMS+ and cardiac MRI was unsatisfactory for measuring right ventricle ejection fraction. • Experts advised that more evidence is needed before VMS+ can be routinely used in the NHS. Experts disagreed about where VMS+ would provide the most benefit in the care pathway. One expert felt that VMS+ would provide little additional value than existing technologies."

Just saying do your own DD-dont invest based on what anyone says here, especially me.
Caveat Emptor.

Graham, one or two experts don't make it so and you know that.

One needs to read the report in totality. There are pluses and minuses.

The National Health Service is not the only healthcare system on this planet.

G1945V